Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic

Q4 Medicine
C. Codreanu, R. Ionescu, D. Predețeanu, E. Rezus, M. Pârvu, C. Mogoșan, C. Popescu, S. Rednic, B. Pharmacy, I. Pharmacy, C. Pharmacy
{"title":"Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic","authors":"C. Codreanu, R. Ionescu, D. Predețeanu, E. Rezus, M. Pârvu, C. Mogoșan, C. Popescu, S. Rednic, B. Pharmacy, I. Pharmacy, C. Pharmacy","doi":"10.37897/rjr.2020.3.1","DOIUrl":null,"url":null,"abstract":"SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the current pandemic, causing so far over 100.000 cases and more than 4500 deaths in Romania. Clinical manifestations are variable, ranging from mild forms (fever, dry cough, dyspnea, tachypnea, asthenia, myalgia) to severe bilateral pneumonia (COV- ID-19). Generally, patients with inflammatory/autoimmune rheumatic diseases have an increased risk of infections compared to the general population, especially if under treatment with immunosuppressive therapies. In the absence of infection or exposure to SARS-CoV-2, the use of specific drugs (non-steroidal anti-inflammatory drugs – NSAIDs; glucocorticoids - GC; conventional synthetic - csDMARDs, targeted synthetic – tsDMARDs and bio- logic disease-modifying anti-rheumatic drugs - bDMARDs, denosumab) should be unaffected. In patients with exposure to SARS-Co V-2, but without symptoms of COVID-19, NSAIDs, hydroxychloroquine, sulfasalazine and, in specific cases, IL-6 inhibitors may be continued, methotrexate, leflunomide, non-anti-IL-6 bDMARDs, tsDMARDs and immunosuppressants should be temporarily discontinued until a negative result for SARS-CoV-2 or for up to 2 weeks asymptomatic state for specific post-epidemiological COVID-19 symptoms. In patients with confirmed or suspected COVID-19 infection, non-anti-IL-6 bDMARDs, tsDMARDs, methotrexate, leflunomide, sulfasalazine and immunosuppressants must be temporarily discontinued. In such particular cases, IL-6 inhibitors and hydroxychloroquine may be continued, depending on the clinical context. In forms with severe respiratory manifestations, NSAIDs must be stopped. In all cases, non-essential medical consultations and maneuvers should be reduced where appropriate, with optimal use of telemedicine. Social distancing, facial masks and constant hand hygiene is advised for all patients, according to national and international recommendations.","PeriodicalId":33518,"journal":{"name":"Revista Romana de Reumatologie","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Romana de Reumatologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37897/rjr.2020.3.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the current pandemic, causing so far over 100.000 cases and more than 4500 deaths in Romania. Clinical manifestations are variable, ranging from mild forms (fever, dry cough, dyspnea, tachypnea, asthenia, myalgia) to severe bilateral pneumonia (COV- ID-19). Generally, patients with inflammatory/autoimmune rheumatic diseases have an increased risk of infections compared to the general population, especially if under treatment with immunosuppressive therapies. In the absence of infection or exposure to SARS-CoV-2, the use of specific drugs (non-steroidal anti-inflammatory drugs – NSAIDs; glucocorticoids - GC; conventional synthetic - csDMARDs, targeted synthetic – tsDMARDs and bio- logic disease-modifying anti-rheumatic drugs - bDMARDs, denosumab) should be unaffected. In patients with exposure to SARS-Co V-2, but without symptoms of COVID-19, NSAIDs, hydroxychloroquine, sulfasalazine and, in specific cases, IL-6 inhibitors may be continued, methotrexate, leflunomide, non-anti-IL-6 bDMARDs, tsDMARDs and immunosuppressants should be temporarily discontinued until a negative result for SARS-CoV-2 or for up to 2 weeks asymptomatic state for specific post-epidemiological COVID-19 symptoms. In patients with confirmed or suspected COVID-19 infection, non-anti-IL-6 bDMARDs, tsDMARDs, methotrexate, leflunomide, sulfasalazine and immunosuppressants must be temporarily discontinued. In such particular cases, IL-6 inhibitors and hydroxychloroquine may be continued, depending on the clinical context. In forms with severe respiratory manifestations, NSAIDs must be stopped. In all cases, non-essential medical consultations and maneuvers should be reduced where appropriate, with optimal use of telemedicine. Social distancing, facial masks and constant hand hygiene is advised for all patients, according to national and international recommendations.
罗马尼亚风湿病学会关于严重急性呼吸系统综合征冠状病毒2型大流行背景下风湿病患者管理的建议
SARS-CoV-2(严重急性呼吸综合征冠状病毒2)是当前大流行的罪魁祸首,迄今已在罗马尼亚造成10万多例病例和4500多人死亡。临床表现多种多样,从轻度(发热、干咳、呼吸困难、呼吸急促、虚弱、肌痛)到严重的双侧肺炎(covid -19)。一般来说,与一般人群相比,患有炎症/自身免疫性风湿病的患者感染的风险增加,特别是在接受免疫抑制疗法治疗的情况下。在没有感染或暴露于SARS-CoV-2的情况下,使用特定药物(非甾体抗炎药-非甾体抗炎药;糖皮质激素- GC;常规合成的csDMARDs、靶向合成的tsDMARDs和生物疾病修饰抗风湿药物(bDMARDs, denosumab)应该不受影响。对暴露于SARS-CoV-2但无COVID-19症状的患者,可继续使用非甾体抗炎药、羟氯喹、磺胺吡啶,在特定情况下,可继续使用IL-6抑制剂,甲氨蝶呤、来氟米特、非抗IL-6 bdmard、tsdmard和免疫抑制剂,直至SARS-CoV-2结果阴性,或对特定的COVID-19流行病学后症状停用长达2周的无症状状态。在确诊或疑似COVID-19感染的患者中,非抗il -6 bDMARDs、tsDMARDs、甲氨蝶呤、来氟米特、柳氮磺胺和免疫抑制剂必须暂时停用。在这种特殊情况下,根据临床情况,可以继续使用IL-6抑制剂和羟氯喹。有严重呼吸道症状的患者必须停用非甾体抗炎药。在所有情况下,应酌情减少非必要的医疗咨询和机动,并最佳地利用远程医疗。根据国家和国际建议,建议所有患者保持社交距离、佩戴口罩和保持手部卫生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
22
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信